In non‐small cell lung cancer, bevacizumab, an anti‐human VEGF monoclonal antibody, first improved patient survival and response rates when combined with carboplatin and paclitaxel54 and later improved progression‐free survival when combined with carboplatin, paclitaxel, and atezolizumab in high PD‐L1‐expressed tumors.55 Here, CD274 is linked to lung cancer.